Litigation Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-05-31 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Patents | 6,264,981; 6,720,001; 6,740,333; 6,967,028; 9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785; 9,937,223 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Biologic Drugs cited in Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-05-31 | 1 | Complaint | United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…(“the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”), and 9,937,223 (“the…the ‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of …copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. …copy of the ‘526 Patent is attached as Exhibit B. Par Pharmaceutical owns the ‘526 Patent. 16. | External link to document |
| 2019-11-18 | 141 | Notice of Service | Kirsch, Ph.D. regarding Infringement of U.S. Patent Nos. 9,687,526, 9,744,209, and 9,750,785 filed by Endo … 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-11-18 | 142 | Notice of Service | .Ph. Concerning Invalidity of U.S. Patent Nos. 9,678,526; 9,744,209; and 9,750,785 (Confidential - Pursuant… 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-12-20 | 161 | Stipulation of Dismissal | regarding Certain Claims of U.S. Patent Nos. 9,744,239, 9,937,223, and 9,375,478 by Endo Par Innovation Company… 31 May 2018 1:18-cv-00823-CFC 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-04-24 | 180 | Exhibits 1-18 to Declaration of Ashley Cade | 6,264,981 Bl 7/2001 Zhang et al. (63) Continuation-in-part… 6,264,981 Bl 7/2001 Zhang et al. … 6,264,981 Bl 7/2001 Zhang et al. (65) …ANDA. ’209 Patent: Claims 1, 3, 4, 5, 7 ’785 Patent: Claims 1, 4, 5, 8 ’526 Patent: Claim 13 …United States Patent (IO) Patent No.: US 9, | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
